Limits...
MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin

View Article: PubMed Central - PubMed

ABSTRACT

It has been demonstrated that microRNA-122 (miR-122) plays key roles in the modulation of hepatitis B virus (HBV) replication. This study examined the role of miR-122 in patients with hepatitis C virus (HCV)-HBV dual infection with active hepatitis C who received pegylated interferon-α and ribavirin dual therapy. We enrolled 121 patients with HCV-HBV dual infection after dual therapy. Stored serum was collected before treatment. RT-PCR was used to analyze miR-122. HBsAg seroclearance was noted in 37 (30.1%) cases during a median follow-up period of 5.4 years. miR-122 was significantly lower in HBsAg seroclearance patients than in non-HBsAg seroclearance patients (P < 0.014). Multivariate analysis showed that miR-122 was an independent factor of HBsAg seroclearance (OR: 0.30, 95% CI: 0.09–0.98, P = 0.046). miR-122 was significantly higher in patients who were qHBsAg > 100 IU/mL versus ≤100 IU/mL (P < 0.001). We concluded that in patients with HBV-HCV dual infection with active hepatitis C, miR-122 was associated with HBsAg seroclearance after therapy and qHBsAg level before therapy, indicating that miR-122 plays key roles in modulating HBV replication.

No MeSH data available.


Related in: MedlinePlus

Kaplan–Meier analysis of independent factors associated with HBsAg seroclearance.qHBsAg: quantitative hepatitis B surface antigen.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036026&req=5

f1: Kaplan–Meier analysis of independent factors associated with HBsAg seroclearance.qHBsAg: quantitative hepatitis B surface antigen.

Mentions: HBsAg seroclearance was noted in 37 (31%) patients during follow-up. The 5-year cumulative probability of HBsAg seroclearance was 27.84% (95% CI = 20.31–37.44), with an average annual rate of 5.57%. Univariate analysis (Table 5) showed that male patients (P = 0.043), age > 60 years (P = 0.003), ALT > 80 IU/mL (P = 0.001), miR-122 ≤ −4(P = 0.014) and qHBsAg < 100 IU/mL (P < 0.001) were associated with HBsAg seroclearance. Multivariate analysis showed that male (OR = 4.43, 95% CI: 1.35–14.58, P = 0.014), age > 60 years (OR = 4.33, 95% CI: 1.40–13.45, P = 0.011), ALT > 80IU/ml (OR:4.24, 95% CI: 1.32–13.62, P = 0.015), miR-122> −4 (OR = 0.30, 95% CI: 0.09–0.98, P = 0.046), and qHBsAg > 100 IU/ml (OR = 0.22, 95% CI: 0.06–0.81, P = 0.023) were independently associated with HBsAg seroclearance. Kaplan–Meier analysis of independent factors associated with HBsAg seroclearance were shown in Figs 1 and 2.


MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin
Kaplan–Meier analysis of independent factors associated with HBsAg seroclearance.qHBsAg: quantitative hepatitis B surface antigen.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036026&req=5

f1: Kaplan–Meier analysis of independent factors associated with HBsAg seroclearance.qHBsAg: quantitative hepatitis B surface antigen.
Mentions: HBsAg seroclearance was noted in 37 (31%) patients during follow-up. The 5-year cumulative probability of HBsAg seroclearance was 27.84% (95% CI = 20.31–37.44), with an average annual rate of 5.57%. Univariate analysis (Table 5) showed that male patients (P = 0.043), age > 60 years (P = 0.003), ALT > 80 IU/mL (P = 0.001), miR-122 ≤ −4(P = 0.014) and qHBsAg < 100 IU/mL (P < 0.001) were associated with HBsAg seroclearance. Multivariate analysis showed that male (OR = 4.43, 95% CI: 1.35–14.58, P = 0.014), age > 60 years (OR = 4.33, 95% CI: 1.40–13.45, P = 0.011), ALT > 80IU/ml (OR:4.24, 95% CI: 1.32–13.62, P = 0.015), miR-122> −4 (OR = 0.30, 95% CI: 0.09–0.98, P = 0.046), and qHBsAg > 100 IU/ml (OR = 0.22, 95% CI: 0.06–0.81, P = 0.023) were independently associated with HBsAg seroclearance. Kaplan–Meier analysis of independent factors associated with HBsAg seroclearance were shown in Figs 1 and 2.

View Article: PubMed Central - PubMed

ABSTRACT

It has been demonstrated that microRNA-122 (miR-122) plays key roles in the modulation of hepatitis B virus (HBV) replication. This study examined the role of miR-122 in patients with hepatitis C virus (HCV)-HBV dual infection with active hepatitis C who received pegylated interferon-&alpha; and ribavirin dual therapy. We enrolled 121 patients with HCV-HBV dual infection after dual therapy. Stored serum was collected before treatment. RT-PCR was used to analyze miR-122. HBsAg seroclearance was noted in 37 (30.1%) cases during a median follow-up period of 5.4&thinsp;years. miR-122 was significantly lower in HBsAg seroclearance patients than in non-HBsAg seroclearance patients (P&thinsp;&lt;&thinsp;0.014). Multivariate analysis showed that miR-122 was an independent factor of HBsAg seroclearance (OR: 0.30, 95% CI: 0.09&ndash;0.98, P&thinsp;=&thinsp;0.046). miR-122 was significantly higher in patients who were qHBsAg&thinsp;&gt;&thinsp;100&thinsp;IU/mL versus &le;100&thinsp;IU/mL (P&thinsp;&lt;&thinsp;0.001). We concluded that in patients with HBV-HCV dual infection with active hepatitis C, miR-122 was associated with HBsAg seroclearance after therapy and qHBsAg level before therapy, indicating that miR-122 plays key roles in modulating HBV replication.

No MeSH data available.


Related in: MedlinePlus